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Abstract
We report a microfluidic sandwich immunoassay constructed around a dual-giant magnetoresistance (GMR) sensor array to
quantify the heart failure biomarker NT-proBNP in human plasma at the clinically relevant concentration levels between 15 pg/
mL and 40 ng/mL. The broad dynamic range was achieved by differential coating of two identical GMR sensors operated in
tandem, and combining two standard curves. The detection limit was determined as 5 pg/mL. The assay, involving 53 plasma
samples from patients with different cardiovascular diseases, was validated against the Roche Cobas e411 analyzer. The salient
features of this system are its wide concentration range, low detection limit, small sample volume requirement (50 μL), and the
need for a short measurement time of 15 min, making it a prospective candidate for practical use in point of care analysis.
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Introduction
Heart failure (HF) is a common, costly, and potentially deadly
condition. In developed countries, around 2% of the adult
population suffers from heart failure. In those over the age
of 65, this percentage increases to 6–10% [1]. By means of
clinical data, a strong association between the N-terminal pro-
B-type natriuretic peptide (NT-proBNP) level and the mortal-
ity in patients with heart failure has been established [2]. NT-
proBNP is considered the gold standard biomarker in heart
failure [3–5].
Currently, detection of NT-proBNP is still confined to
the medical laboratory. The analysis is based on conven-
tional immunoassay tests, whose results may require sev-
eral hours or even days to be delivered [6]. Rapid and
easily performed NT-proBNP quantification in human
blood could reduce the time requirement, and would allow
for real-time monitoring, even by the patient. Such person-
alized diagnostics option may avoid unnecessary or im-
proper treatment and hospital admission, which for the
benefit of the patient aids in preventing permanent heart
damage, and ultimately results in reduced medical ex-
penses and preserved resources.
Point-of-care testing (POCT) is a rapid and simple means
for diagnosing diseases which could be done by health care
workers without technical training [7]. Superior to traditional
laboratory detection, POCT can be performed at bedside by
non-laboratory-trained personnel and increase efficiency to
clinical decision-making about additional testing or guiding
therapy [8]. Time of transport and preparation of clinical sam-
ples can be reduced, and test results are rapidly available at the
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as soon as the symptoms appear; therefore, the mortality and
morbidity can be effectively decreased [9, 10].
With the advent of microfluidics technology, it has become
established that microfluidics is particularly suitable for
POCT, due to its intrinsic merits of low reagent and sample
consumption, low cost, and the possibility of integration with
miniaturized detectors [11–14]. Microfluidics has, for exam-
ple, been combined with various immunosensing elements for
glucose, various ions, proteins, and DNA. In 1992, Abbot
Point of Care Inc. introduced the i-Stat system, utilizing
microfluidics technology to quantify various inorganic cations
and glucose [15]. The i-Stat testing cartridge was subsequent-
ly expanded to allow for the quantitative measurement of car-
diac troponin I in whole blood or plasma [16]. Similarly, the
Triage cardiac panel by Biosite Inc. is based on fluorescence
immunosensing in a microfluidic chip format, and can detect
three cardiac biomarkers simultaneously [17].
Giant magnetoresistance (GMR) is the change in resistance
of some materials in response to an applied magnetic field.
GMR technology was initially exclusively used to read data in
hard disk drives, but has since become widespread in biomed-
ical sensing applications. For example, Schotter et al. had
shown that the GMR sensor was more sensitive than compa-
rable standard fluorescent DNA detection [18]. Zhi et al. had
developed a novel HBV genotype detecting system based on
the GMR sensor, and magnetic nanoparticles (MNPs) [19].
Gaster et al. adopted GMR sensors for quantification of pro-
tein interactions [20]. GMR sensing technology combines
high sensitivity with portability, low cost, and real-time detec-
tion. In addition, the fabrication of GMR sensors is compatible
with conventional cleanroom technologies devised for mass
production, so the cost of GMR sensors can be greatly re-
duced, enabling the development and fabrication of POCT
devices.
In this paper, we present a dual-sensor POCT chip device,
combining sandwich immunoassays with a microfluidic sam-
ple handling device. The two integrated GMR sensors utilized
in tandem in the assay system are individually coated with
detection antibodies of different affinity to the antigen, leading
to differential binding at different concentration ranges, which
extends the dynamic range of the tandem detector, compared
to the individually operated devices (Fig. 1). On the other
hand, compared with the currently commercial kit, the devel-
oped POCT chip device can be performed more easily at bed-
side by non-laboratory-trained personnel, which just needed
sample injecting and chip inserting. The integrated
microfluidic assay reduced the sample volume requirement
and was very suitable for multi-detection.
In order to widen the measurement range to cover the con-
centrations relevant for HF diagnosis, we used two kinds of
capture antibodies (Fig. 1a). In the presence of low concentra-
tions of antigen, capture antibody Ab1, deposited on sensor I,
generates a response on GMR sensor I. With increasing
concentration of antigen, GMR sensor I becomes eventually
saturated, while the response of sensor II increases. In the
intermediate situation with moderate analyte concentration,
we combined the two signals by means of averaging the stan-
dard curves obtained from the two sensors at their respective
overlapping concentration ranges.
The clinically relevant concentration range for NT-
proBNP, determined with commercial assays (e.g., Roche
Diagnostics Elecsys® proBNP Immunoassay), is between
5 pg/mL and 35,000 pg/mL. The recommended clinical
threshold has been suggested as 125 pg/mL for patients youn-
ger than 75 years of age, and 450 pg/mL for patients 75 years
and older. For the latter case, NT-proBNP < 300 pg/mL is
indicative of the absence of acute HF [21].
Materials and methods
Reagents
All reagents used in this work were of analytical grade.
Potassium dihydrogen phosphate (KH2PO4), sodium
dihydrogen phosphate (NaH2PO4), potassium chloride
(KCl), and sodium chloride (NaCl) were obtained from Alfa
Aesar. Tween 20 was obtained from AMRESCO (USA). For
the detection of NT-proBNP antigens, two anti-NT-proBNP
monoclonal antibodies (Ab1, 15C4, and Ab2, 11D1) were
combined as capture antibody, and one anti-NT-proBNP
monoclonal antibody (Ab3, 13G12) as detection antibody.
All antibodies as well as recombinant NT-proBNP were pur-
chased from HyTest, Ltd. (Finland). Clinical human plasma
samples were provided by the Peking University Shenzhen
Hospital. The detection antibody was biotinylated using
NHS-biotin (Alfa Aesar) [22].
Avidin-coated MNPs used as magnetic tags were pur-
chased from Ademtech, Ltd. (France). A sample of
polystyrene-grafted-maleic anhydride (PS-g-MA, graft ratio
17%) was provided as a free sample by Longjia Plastics
Fabrication (Jilin, China).
The assay cartridge (Fig. 2) was developed by Dongguan
Bosh Biotechnologies, Ltd. (China), and is part of a GMR-
based assay processor. Figure 2b shows the main components
of the assay cartridge. Details have been published elsewhere
[23]. The cartridge consists of a 20-unit GMR sensor array on
a 2 mm× 2.3 mm chip, integrated into a microfluidic sample
handling unit with on-chip wells.
Device preparation
The GMR sensor used in this study is a multilayer thin-film
structure on a Si wafer (Si (450 μm)/SiO2 (10 nm)) composed
of Ta (4.5 nm)/PtMn (10 nm)/CoFe (2 nm)/Cu (2 nm)/CoFe
(1 nm)/NiFe (3 nm)/Al2O3 (40 nm). The chip (Fig. 2c) has a
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size of 2.0 mm× 2.3 mm, and contains 20 individual GMR
sensor units with a diameter of 90 μm each.
The sensor surface (Fig. 2d) was modified by spin coating
with PS-g-MA toluene solution (1% w/v) [24], using a spin
coater (KW-4A, Institute of Microelectronics of the Chinese
Academy of Sciences, I: 800 rpm, 30 s, II: 2000 rpm, 60 s).
The specimen was subsequently dried at 60 °C in thermal
convection oven (ZD-85, Jintan Jincheng Guosheng
Experimental Instrument Factory, China) for 10 min. The
two capture antibody solutions (50μg/mL in carbonate buffer,
0.1 M, pH = 9.6) were printed onto the specified positions of
the sensor array surface by means of a Nano-Plotter NP 2.1
(GeSiM, Germany) and incubated at 37 °C and 70% humidity
for 30 min.
Prior to assembly of the assay cartridge (Fig. 2b), the de-
tection antibody and the MNP were pipetted onto designated
areas of the channel layer (Fig. 2a), and freeze-dried. This
allowed for storage of the prepared device for up to 6 months.
Assay procedure
The surfaces of the sensor units were pre-coated with the
recognition antibodies (Fig. 1a. Nanoparticles and detection
antibodies were also pre-deposited on the cartridge (cf. Fig.
2b), to be re-hydrated during the assay. The sandwich assay
protocol consists in the first step of an immunoreaction of
antigen (sample or standard), introduced through designated
on-chip wells, with detection antibodies. Simultaneously, the
antigen binds to the capture antibodies on the surface, forming
the assay sandwich (5 min at RT, Fig. 1b, c). Subsequently,
the binding to avidin-coated magnetic nanoparticles (dis-
solved in carbonate buffer, 0.1 M, pH = 9.6) is initiated
(5 min at RT, Fig. 1d). Intermittent washing steps (10 mM
PBS, pH = 7.4, 0.5% Tween 20) are applied in between the
binding reactions. The captured MNPs (Fig. 2d) are finally
detected by the GMR sensors (Fig. 2e), the outputs of which
are processed in order to obtain the calibration curves and
sample measurements. The entire assay process is completed
within 15 min.
Data collection and processing
For the construction of the calibration curves, three reference
measurements were performed per data point, and means and
standard deviations were calculated. A total of 58 patient sam-
ples were analyzed; one measurement was performed per
Fig. 1 The assay protocol. a Surface modification. Sensor I and II
represent the different GMR sensors, and Ab1 and Ab2 represent the
respective capture antibodies. b Sample loading and detection antibody
binding. Yellow dots represent the biotin tags for binding to the avidin-
coated magnetic nanoparticles. c Analyte binding. d Magnetic particle
binding and detection
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patient sample. We obtained two standard curves for the two
individual sensor responses, reflecting the difference in bind-
ing affinity, and thus antigen concentration. The standard
curve A covers the concentration range from 15 to 5000 pg/
mL, and standard curve B covers the range from 100 to
40,000 pg/mL. The values for the middle range from 100 to
5000 pg/mL were determined by calculating the mean of the
individual sensor-specific concentrations obtained from stan-
dard curves A and B.
Results
Optimization of detection performance
We investigated the effects of magnetic field intensity and the
size of the MNPs on the measurement performance. The in-
fluence of the magnetic field strength on the immune reaction
was observed in the presence of 0 (blank), 100 (low concen-
tration reference standard), and 5000 (high concentration ref-
erence standard) pg/mL NT-proBNP. With increasing mag-
netic field strength, the background noise, as determined from
the blank measurement, and the detection signal increase ac-
cordingly (Fig. 3a). The S/N ratio for the low concentration
reference standard has its maximum value at a field strength of
3 mT (30 G). A field of 3 mT shows acceptable performance
for both low and high concentration standards of NT-proBNP.
Consequently, a 3-mT field was used in the experiments.
We investigated the relationship between the maximum
response signal and the size of magnetic particles used in the
individual assays. We found that the magnitude of the maxi-
mum response is increasing with particle size, and more than
doubles over the range between 50 and 500 nm (Fig. 3b).
However, with particles of Ø 200 nm and larger, the back-
ground increased such that the S/N decreases sharply. It is
likely that larger particles have the tendency to remain in the
detection area due to non-specific adsorption to the sensor
surface. We conclude that the optimal size of the MNPs is
100 nm for this assay, and have chosen this size for all
experiments.
Calibration of the NT-proBNP assay
Using the optimal system parameters, the relationships be-
tween rate of resistance change and concentration of NT-
proBNP (Fig. 4) was determined for both sensors. Standard
curve A is the plot of the calibration function of the antigen
concentration (linear fit with log c as variable) from 15 to
5000 pg/mL (Y = 0.0263X0.595, r = 0.994), standard curve B
is the same for sensor B and 100 to 40,000 pg/mL (Y =
Fig. 2 The assay system used in the experiments. a Schematic drawing of
the chip layout [23]. The deposition areas for avidin-coated magnetic
particles (MP) and biotinylated detection antibodies (Ab) are marked.
Wc, waste cavity; Wac, washing buffer cavity; Sc, sample cavity; MPc,
magnetic nanoparticle rehydration buffer cavity; Rc, reaction cavity. b
POCT cartridge, consisting of the microfluidic sample handling circuitry
with on-chip cavities, the sensor array chip, and a contact pad interface. c
GMR sensor array. The two selected sensor units SI and SII used in
tandem are marked in yellow. Two uncoated sensors (TC) used for cal-
culating a compensating factor to account for temperature changes during
the measurement are marked in red. d Magnification of a single sensor
unit, covered with a droplet of capture antibody during incubation. The
border between droplet and sensor surface (silicon wafer chip) gives
under the microscope the impression of a shallow cavity. e SEM micro-
graph of the sensor surface after MNP (gray spheres) binding
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0.0103X0.590, r = 0.998). The limit of detection (3S/N) was
found to be 5 pg/mL.
Validation
The assay results obtained with the GMR detection system
were validated against the Roche Cobas e411 assay (Fig. 5).
Passing-Bablok regression analysis yielded the following
equation for the data set covering the entire concentration
range (n = 53): y = 1.02x + 10.68; r = 0.995 (Fig. 5a). The
95% confidence interval for the slope is 1.00 to 1.05, and for
the y intercept, the 95% confidence interval is − 70.06 to
91.42. Figure 5b shows the Bland-Altman plot of the relative
differences between the data sets of both assays. The mean
relative difference (95% confidence limit) is 1.9% (− 47.2 to
43.3%). There is no statistically significant bias between the
two assays.
Discussion
The tandem operation of two GMR sensors with different
dynamic ranges in a microfluidic sample handling cartridge
expands the dynamic range to cover the full clinically relevant
concentration range of NT-proBNP. In the commercial assay
analyzer, the sensors in the array are used in parallel for repeat
measurements, but not in tandem.
In order to apply differential antibody coating to the
GMR sensors, a facile surface modification method based
upon the functional polymer PS-g-MAH was introduced,
using a combination of spin coating and nano-plotting. A
1% solution of the polymer was used in the procedure,
since earlier studies revealed that at that concentration,
the film quality was such that the highest degree of surface
immobilization of antibody could be achieved, while the
film quality was highest. The roughness of the film in-
creased with greater polymer concentration. It is conceiv-
able that the optimal concentration can vary for different
antibodies, but this was not investigated further. A slight
drawback for further application development is the cur-
rently limited commercial availability of research amounts
of the grafting polymer, although the material itself is pro-
duced on a large scale for plastics consumer goods. One
cartridge is required per assay; re-use strategies should be
investigated for improved sustainability.
The approach is open for surface functionalization with
different antibodies, making the assay concept easily expand-
able to a wide variety of analytes.
Data treatment by means of two combined standard curves
increased the detection range for a single assay by one order of
magnitude. Validation against a commercial assay revealed
that the accuracy of the method would be acceptable in a
clinical testing setting. The assay’s lightweight instrumental
back end, short measurement time of ~ 15 min, and simple
operation are beneficial pre-requisites for point of care appli-
cation. The required sample size is only 50 μL.
Fig. 3 Optimization of the detection (n = 3). a The dependence of
detector signal (bars) and signal to noise ratio (S/N, lines) on the
magnetic field intensity. Hollow squares: S/N of the low concentration
reference standard; hollow circles: S/N of the high concentration refer-
ence standard. b The influence of the size of magnetic particle on the
detector response (bars), and the S/N ratio (line)
Fig. 4 The standard curves (n = 3) obtained with a low concentration
reference standard on GMR sensor I (black line) and a high
concentration reference standard on GMR sensor II (red line). Each
data point is the average of three repeat measurements, each carried out
using a single assay cartridge. The error bars indicate ± 1 σ
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Although some essential figures of merit of the new tandem
method are comparable to the established commercial assay
processor as well as to the Roche analyzer used in the valida-
tion study, e.g., LOD and LOQ (Table 1); others were clearly
improved.
The most important aspect is the abovementioned range ex-
pansion. This is coupled to a reduced time and lower sample
requirement for a full range analysis: both are influential perfor-
mance parameters in order to achieve a high degree of portability
and simplicity expected from POC instrumentation.
Concluding remarks
Wehave presented a promising sample handling and detection
system for wide-range quantitative NT-proBNP determination
in human plasma, with favorable figures of merit as well as
distinct operational benefits. The tandem operation of several
GMR units on the same chip is a technical framework for
functionally combining identical sensing units. One alterna-
tive to be explored is the use of different assay formats on the
same lab on a chip, which can be most likely implemented
without changes to the chip or sensor design. For example, by
a combination of a competitive and a sandwich assay, the
hook effect can be directly detected in order to effectively
cover the full diagnostic concentration range of a biomarker.
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